Anindita Sinha

Anindita (Ani) Sinha is currently the Pipeline US Market Access Lead for Immunology at Boehringer Ingelheim. Previously, she was at Pfizer where she held several US and Global strategic leadership roles including Senior Director of Business Operations and Director of Global Market Access, Inflammation & Immunology. In her Market Access role, she was responsible for developing and leading access launch strategies for several novel immunology compounds including the successful global launch of Crisaborole (Eucrisa).

Prior to working for Pfizer, Anindita held multiple roles of increasing responsibility, including Director of Business Insights for Corporate and Government Customers at Bayer pharmaceuticals.  In this role, she was responsible for leading the business analytics team supporting US Managed Markets and brand support for all six specialty pharmaceutical business units (Dermatology, Oncology, Rare diseases (Hemophilia and Cardiopulmonary) and Neurology (Multiple Sclerosis).

In addition, Anindita worked for Celgene Corporation, leading the market access analytics function for the US team and held various consulting positions at both Campbell Alliance (now Syneos) and Navigant Consulting (now Guidehouse) where she led engagements focused on US and global payer strategies.

Anindita holds a M.Phil in Microbiology from Yale University in New Haven, CT and a BA in Biochemistry from Columbia University in New York.

Anindita currently splits her time between NYC and Somers, NY with her husband and her green cheek conure, Kilo.  A long-time city dweller, she spent her free time exploring the nearby theater scene and finding the next best hidden restaurant (pre-COVID-19).